These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 37517128)
1. Guideline-Directed Low-Density Lipoprotein Cholesterol Management After Acute Ischemic Stroke: Findings from a National Health Care Service. Zafrir B; Aker A; Naoum I; Saliba W Am J Cardiol; 2023 Sep; 203():332-338. PubMed ID: 37517128 [TBL] [Abstract][Full Text] [Related]
2. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice. Sabouret P; Puymirat E; Kownator S; Abdennbi K; Lebeau F; Meltz M; Angoulvant D; Schiele F Panminerva Med; 2023 Jun; 65(2):244-249. PubMed ID: 36222543 [TBL] [Abstract][Full Text] [Related]
3. 2017 Taiwan lipid guidelines for high risk patients. Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI; J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176 [TBL] [Abstract][Full Text] [Related]
4. [The importance of intensive lipid-lowering therapy after acute coronary syndrome: changing the paradigm to improve the achievement of targets]. Muccioli S; Giglio C; Annibali G; Cerutti E; Civera S; Casati R; Delnevo F; De Rosa C; Bongioanni S; Colopi M; Gandolfo N; Aranzulla T; Bianchi F; Blandino A; Borrione M; Grossi S; Luceri S; Mabritto B; Carceri C; Meliga E; Parrini I; Pizzuti A; Scrocca I; Sibona Masi A; Tomasello A; Gasco A; Musumeci G G Ital Cardiol (Rome); 2022 Jul; 23(7):553-561. PubMed ID: 35771021 [TBL] [Abstract][Full Text] [Related]
5. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335 [TBL] [Abstract][Full Text] [Related]
6. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N BMJ; 2022 May; 377():e069066. PubMed ID: 35508320 [TBL] [Abstract][Full Text] [Related]
7. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials. Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949 [TBL] [Abstract][Full Text] [Related]
8. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699 [TBL] [Abstract][Full Text] [Related]
9. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study. Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890 [TBL] [Abstract][Full Text] [Related]
12. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. Amarenco P; Kim JS; Labreuche J; Charles H; Abtan J; Béjot Y; Cabrejo L; Cha JK; Ducrocq G; Giroud M; Guidoux C; Hobeanu C; Kim YJ; Lapergue B; Lavallée PC; Lee BC; Lee KB; Leys D; Mahagne MH; Meseguer E; Nighoghossian N; Pico F; Samson Y; Sibon I; Steg PG; Sung SM; Touboul PJ; Touzé E; Varenne O; Vicaut É; Yelles N; Bruckert E; N Engl J Med; 2020 Jan; 382(1):9. PubMed ID: 31738483 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691 [TBL] [Abstract][Full Text] [Related]
14. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356 [TBL] [Abstract][Full Text] [Related]
15. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
16. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068 [TBL] [Abstract][Full Text] [Related]
17. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Daskalopoulou SS; Mikhailidis DP Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035 [TBL] [Abstract][Full Text] [Related]
18. Optimizing Post-Acute Coronary Syndrome Dyslipidemia Management: Insights from the North American Acute Coronary Syndrome Reflective III. Alanezi M; Yan AT; Tan MK; Bourgeois R; Malek-Marzban P; Beharry R; Alkurtass S; Gyenes GT; Nadeau PL; Nwadiaro N; Jedrzkiewicz S; Gao D; Chandna H; Nelson WB; Goodman SG; Cardiology; 2024; 149(3):266-274. PubMed ID: 38290490 [TBL] [Abstract][Full Text] [Related]
19. Evidence-based goals in LDL-C reduction. Soran H; Dent R; Durrington P Clin Res Cardiol; 2017 Apr; 106(4):237-248. PubMed ID: 28124099 [TBL] [Abstract][Full Text] [Related]
20. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]